
Ashraf H Elghandour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6626114/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695
2	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	13.9	401
3	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 2016, 127, 713-721.	0.6	121
4	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2016, 3, e506-e515.	2.2	121
5	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia, 2019, 33, 1173-1183.	3.3	83
6	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. Blood, 2015, 126, 505-505.	0.6	67
7	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. British Journal of Haematology, 2017, 179, 66-74.	1.2	16
8	Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematology Reports, 2009, 1, 6.	0.3	14
9	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. Blood, 2011, 118, 3976-3976.	0.6	12
10	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma Journal of Clinical Oncology, 2014, 32, 8510-8510.	0.8	9
11	Study of microRNA Profile as a Molecular Biomarker in Egyptian Chronic Lymphocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 89-99.	0.3	5
12	Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. Blood, 2015, 126, 3026-3026.	0.6	5
13	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Mveloma, Blood, 2014, 124, 2120-2120.	0.6	4
14	Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. Blood, 2014, 124, 4742-4742.	0.6	3
15	Level of Pentraxin-3 in Patients with Acute Leukemia in Septicemia and Its Prognostic Value. International Blood Research & Reviews, 2015, 4, 1-7.	0.1	2
16	The clinical significance of the alternative Wilms tumor gene overexpression–hypermethylation signature in acute myeloid leukemia. Clinical and Translational Oncology, 2019, 21, 864-873.	1.2	1
17	Second Report of Arab Leukemia Net (ALN) Registry for Chronic Myeloid Leukemia (CML) in the Middle East &North Africa Region (AFME). Epidemiology of CML and Additional Chromosomal Abnormalities (ACAs) in Egypt, Multicenter Results. Blood, 2014, 124, 5539-5539.	0.6	1
18	Hypothalamic-pituitary dysfunction following external cranial irradiation. European Journal of Cancer, 2001, 37, S201.	1.3	0

#	Article	IF	CITATIONS
19	6036 POSTER Low dose thalidomide as maintenance in multiple myeloma. European Journal of Cancer, Supplement, 2007, 5, 355.	2.2	0
20	Fine needle aspiration as a diagnostic technique in B-cell non-hodgkin lymphoma. Experimental Hematology, 2014, 42, S61.	0.2	0
21	Subgroup Analysis by Prior Treatment of the Efficacy and Safety of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the PANORAMA 1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e78.	0.2	0
22	Quantitative assessment of MLAA-34 expression in a sample of Egyptian patients with acute myeloblastic leukemia. The Egyptian Journal of Haematology, 2014, 39, 232.	0.0	0
23	Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study Journal of Clinical Oncology, 2015, 33, 8575-8575.	0.8	0
24	Early Parenteral Supplementation with Glutamine Dipeptide for Acute Myeloid Leukaemia Patients Receiving High Dose Chemotherapy. Journal of High Institute of Public Health, 2015, 45, 42-51.	0.1	0
25	Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment. Blood, 2015, 126, 4230-4230.	0.6	0